samedan logo

 
 
spacer
home > ebr > spring 2003 > meptides: a novel class of synthetic peptide derivatives for the potential treatment of neurodegenerative diseases
PUBLICATIONS
European Biopharmaceutical Review

Meptides: A Novel Class of Synthetic Peptide Derivatives for the Potential Treatment of Neurodegenerative Diseases

A number of seemingly unrelated neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's diseases, CJD (the human form of 'mad cow' disease) and ALS (motor neurone disease) have all recently been linked to a common pathogenic process called amyloidosis. In each case a specific protein or peptide clumps together in a specific part of the brain to form toxic soluble oligomers and/or insoluble fibres, which are widely believed to cause the progressive degeneration of neurons associated with these diseases. Several academic groups and at least one biotech company are now working on a novel class of synthetic peptide derivatives ('meptides') which can inhibit and reverse this process of protein/peptide aggregation in vitro, and which have the potential to yield effective treatments or perhaps even outright cures for all these diseases.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Kelvin Stott, Chief Scientific Officer, and Andrew J Doig, Research Director, at Senexis Limited

Kelvin Stott is the Chief Scientific Officer and a Co-Founder of Senexis Limited. Before forming Senexis, he gained his PhD and studied the mechanism of Huntington's disease as a Research Fellow at Cambridge University. He then spent two years working in the pharmaceutical sector as a management consultant at McKinsey & Company.


Andrew J Doig is a Senior Lecturer in the Department of Biomolecular Sciences at UMIST and Research Director of Senexis. He undertook research at Cambridge and Stanford Universities before taking a lectureship at UMIST in 1994. His research interests include protein structure and bioinformatics, as well as amyloid.

spacer
Kelvin Stott
spacer
spacer
spacer
Andrew J Doig
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck to Provide BioReliance® End-to-End Solutions to Phanes Therapeutics

• Collaboration to accelerate development and manufacturing of Bispecific Antibody • Merck plans to offer Phanes a full suite of products and services under its BioReliance® offering
More info >>

White Papers

Environmental Factors in Data Centres

Dycem

In addition to temperature and humidity, there are many more constraints in the environment that increase failure rates, explains Emilio Sapiña of Secure Techincal Rooms.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement